

What do Oncologists want?

Structured Decision-Making

71/63

Percentages of oncologist who find high value in NCCN/ASCO frameworks in decision making

Integration of PROs

90

Percentage of oncologists who believe patient reported outcomes (PROs) are valuable in treatment

20

Percentage of oncologists who believe they have the ability to gather PRO data

Focused Training

77

Percentage of oncologists willing to refer patients to clinical trials if more info on off-label use is available

37

Percentage of community oncologists who want to learn more about health economics

Biosimilar Access & Use

25

Percentage of community oncologists who lack familiarity with biosimilar s

20

Percentage of Canadian patients familiar with biosimilars

76

Percentage of oncologists who require an 11-30% discount for biosimilars

Proliferation of CAR-T

72

Percentage of community oncologists who believe manufacturing and logistics is the #1 barrier to use CAR-T therapy

30

Percentage of community oncologists who plan to administer CAR-T themselves; rest plan to refer to centers

Based on analysis of all 2014 abstracts from ISPOR 2017. Percentages reflect the study's sample population only.